Bank of America just raised its EUR/USD forecast
NEW YORK - OS Therapies, Inc. (NYSE-A: OSTX), a biotechnology firm focusing on cancer immunotherapies and targeted drug conjugates, with a current market capitalization of $37 million, has provided a corporate update highlighting significant clinical and financial advancements, particularly within its osteosarcoma program. The company, whose stock has declined over 56% in the past six months according to InvestingPro data, has shared optimistic clinical data and outlined the strategic steps taken to secure its financial position and regulatory milestones. InvestingPro analysis indicates the stock is currently undervalued, with analysts maintaining a strong buy consensus.
In January 2025, OS Therapies completed a $7.1 million financing round, following an initial public offering of $6 million in August 2024. These funds are earmarked for finalizing the OST-HER2 osteosarcoma trial payments, manufacturing for FDA approval, and other operational costs, including the commercialization of the product. InvestingPro data shows the company is quickly burning through cash, with a current ratio of 0.76, indicating potential liquidity challenges. The company’s cash reserves are projected to sustain operations well into mid-2026.
The OST-HER2 program, OS Therapies’ leading asset, recently met its primary endpoint in a Phase 2b clinical trial, showing promise in preventing recurrent, fully resected lung metastatic osteosarcoma. The trial data indicated a significant improvement in Event Free Survival rates compared to historical controls, suggesting a potential shift in the treatment paradigm for this deadly disease.
Moreover, the company is preparing for a Biologics Licensing Application (BLA) submission, expected in the second quarter of 2025, and anticipates FDA approval within six months of filing. If approved, OST-HER2 could qualify for a Priority Review Voucher under the FDA’s Rare Pediatric Disease Designation, potentially bringing in non-dilutive capital estimated around $150 million. Analyst price targets range from $9 to $20 per share, significantly above the current trading price of $1.75.
OS Therapies also announced the strategic acquisition of clinical and intellectual property assets from Ayala, including two Listeria-based immunotherapy candidates for lung and prostate cancer. This acquisition not only expands the company’s clinical portfolio but also significantly reduces anticipated cash milestones and royalty rates, enhancing profit margins for OST-HER2.
In addition to its clinical developments, OS Therapies is exploring strategic options for its tunable Antibody Drug Conjugate platform, which offers innovative drug delivery methods for cancer treatment.
The company’s recent progress, particularly in securing funding and advancing regulatory milestones, positions OS Therapies favorably in a challenging biotech funding environment. With an overall Financial Health score of "Fair" according to InvestingPro, which offers 8 additional key insights about the company’s performance, the focus remains on bringing OST-HER2 to market and improving outcomes for patients with osteosarcoma and other solid tumors. This update is based on a press release statement from OS Therapies.
In other recent news, OS Therapies Inc, a biopharmaceutical company, has made several significant financial and clinical developments. The company recently completed a private placement, raising approximately $7.1 million, which is expected to strengthen its financial position. Additionally, OS Therapies concluded another private placement round, raising around $1.05 million, and secured $6 million through a separate private placement of securities.
In terms of clinical advancements, OS Therapies reported positive results from its Phase 2b clinical trial for OST-HER2, an immunotherapy candidate for recurrent lung metastatic osteosarcoma. The trial showed a promising 33.3% 12-month Event Free Survival rate for patients treated with OST-HER2. Interim analyses of the secondary endpoint, 3-year overall survival, also indicated a favorable trend for patients treated with the therapy.
These recent developments are part of OS Therapies’ ongoing efforts to advance its research and development initiatives. The funds raised from the private placements are intended to support the company’s continued research and development, especially towards achieving clinical and regulatory milestones for OST-HER2. Please note that these are recent developments and do not offer a comprehensive view of the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.